UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
Condition(s):Mesothelin-positive Advanced Malignant Solid TumorsLast Updated:May 12, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Mesothelin-positive Advanced Malignant Solid TumorsLast Updated:May 12, 2023Recruiting
Condition(s):Mesothelin Positive TumorsLast Updated:October 12, 2016Unknown status
Condition(s):Mesothelin-positive Advanced Malignant Solid TumorsLast Updated:March 24, 2023Not yet recruiting
Condition(s):Solid Tumor, AdultLast Updated:August 10, 2020Unknown status
Condition(s):Solid Tumor, Adult; Advanced CancerLast Updated:January 24, 2017Unknown status
Condition(s):Mesothelin-positive Advanced Refractory Solid TumorsLast Updated:March 1, 2023Withdrawn
Condition(s):Epithelial Ovarian CancerLast Updated:January 31, 2019Unknown status
Condition(s):Solid Tumor, AdultLast Updated:November 20, 2018Unknown status
Condition(s):Stage IV Ovarian Cancer; Testis Cancer, Refractory; Endometrial Cancer Recurrent; CAR NKLast Updated:January 9, 2024Recruiting
Condition(s):Esophageal Cancer; AdenocarcinomaLast Updated:October 3, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.